Risankizumab versus adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal.

Like Comment

Patients with moderate-to-severe plaque psoriasis have greatly benefited from the availability of biologics. However, treatment-selection can be challenging and it is important that with growing numbers of biologics available, head-to-head trials comparing efficacy and safety outcomes are undertaken. Most head-to-head trials comparing newer classes of biologics to tumour necrosis factor-α inhibitors have compared with etanercept, which is less commonly used than adalimumab.

Click here to read the full article @ The British journal of dermatology


The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
0 Following